Tenax Therapeutics (TENX) Receives Coverage Optimism Rating of 0.03
News coverage about Tenax Therapeutics (NASDAQ:TENX) has been trending somewhat positive on Sunday, Accern Sentiment reports. Accern ranks the sentiment of news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Tenax Therapeutics earned a media sentiment score of 0.03 on Accern’s scale. Accern also gave news coverage about the specialty pharmaceutical company an impact score of 45.6257847066352 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near future.
NASDAQ:TENX traded down $0.19 during mid-day trading on Friday, reaching $5.37. 3,234 shares of the company’s stock were exchanged, compared to its average volume of 7,112. Tenax Therapeutics has a one year low of $4.40 and a one year high of $12.63.
Tenax Therapeutics (NASDAQ:TENX) last released its quarterly earnings results on Tuesday, August 14th. The specialty pharmaceutical company reported ($1.29) EPS for the quarter, missing analysts’ consensus estimates of ($1.00) by ($0.29). equities research analysts anticipate that Tenax Therapeutics will post -5.85 earnings per share for the current year.
About Tenax Therapeutics
Tenax Therapeutics, Inc, a specialty pharmaceutical company, focused on the identification, development, and commercialization of a portfolio of products for the critical care market in the United States and Canada. It focuses on the development and commercialization of pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion/5ml vial for use in the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome.
Read More: What is the NASDAQ Stock Market?
Receive News & Ratings for Tenax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.